Mayne Pharma Group Ltd (STU:HG6)

€ 2.96 0 (0%) Market Cap: 247.26 Mil Enterprise Value: 179.89 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 72/100

Full Year 2024 Mayne Pharma Group Ltd Earnings Call Transcript
Aug 22, 2024

€2.34

Earnings
Half Year 2024 Mayne Pharma Group Ltd Earnings Call Transcript
Feb 25, 2024

Earnings
Mayne Pharma Group Ltd at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Mayne Pharma Group Ltd Annual Shareholders Meeting Transcript
Nov 29, 2023
Q1 2024 Mayne Pharma Group Ltd Market Update Call Transcript
Oct 17, 2023
Full Year 2023 Mayne Pharma Group Ltd Earnings Call Transcript
Aug 30, 2023

Earnings
Mayne Pharma Group Ltd at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Mayne Pharma Group Ltd Investor Update Call Transcript
May 09, 2023
Half Year 2023 Mayne Pharma Group Ltd Earnings Call Transcript
Feb 27, 2023

Earnings
Mayne Pharma Group Ltd Annual Shareholders Meeting Transcript
Nov 29, 2022
Full Year 2022 Mayne Pharma Group Ltd Earnings Call Transcript
Aug 25, 2022

Earnings
Half Year 2022 Mayne Pharma Group Ltd Earnings Call Transcript
Feb 24, 2022

Earnings
Mayne Pharma Group Ltd Annual Shareholders Meeting Transcript
Nov 22, 2021
Full Year 2021 Mayne Pharma Group Ltd Earnings Presentation Transcript
Aug 26, 2021
Half Year 2021 Mayne Pharma Group Ltd Earnings Presentation Transcript
Feb 23, 2021
Mayne Pharma Group Ltd Annual Shareholders Meeting Transcript
Nov 23, 2020
Full Year 2020 Mayne Pharma Group Ltd Earnings Call Transcript
Aug 20, 2020

Earnings
Half Year 2020 Mayne Pharma Group Ltd Earnings Presentation Transcript
Feb 20, 2020
Full Year 2019 Mayne Pharma Group Ltd Earnings Presentation Transcript
Aug 23, 2019
Q3 2019 Mayne Pharma Group Ltd Trading Update Call Transcript
May 14, 2019
Half Year 2019 Mayne Pharma Group Ltd Earnings Presentation Transcript
Feb 21, 2019

Half Year 2023 Mayne Pharma Group Ltd Earnings Call Transcript

Feb 27, 2023 / 10:00PM GMT

Transcript

Operator

Thank you for standing by, and welcome to the Mayne Pharma Group Limited Half Year 2023 Results Briefing. (Operator Instructions) I will now hand the conference over to Mr. Shawn Patrick O'Brien, CEO. Please go ahead.

Shawn Patrick Oâ;Brien

Mayne Pharma Group Limited - CEO, MD & Director

Thank you. And apologies, everyone, for the technical difficulties. We had to try 3 different ways to get connected here. So sorry for the delay.

Good day, and welcome to the Mayne Pharma half year results conference call. At this time, I'm taking over the conference call with myself, CEO and Managing Director of Mayne Pharma; and my colleague here, Aaron Gray, our Chief Financial Officer. Based on the feedback from our investors, this presentation has a lot more information included than normal. We will not be covering the details of every slide, but wanted you to have a comprehensive depth for your reference going forward.

The next slide, please, is our disclaimer slide, and I'll leave that for you to review. And Slide 3, as announced

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.